Skip to main content
Erschienen in: Inflammation 4/2016

11.06.2016 | ORIGINAL ARTICLE

Statins and IL-1β, IL-10, and MPO Levels in Gingival Crevicular Fluid: Preliminary Results

verfasst von: Vuslat Cicek Ari, Yagmur Deniz Ilarslan, Baran Erman, Bahram Sarkarati, Ilhan Tezcan, Erdem Karabulut, Serife Gul Oz, Mine Durusu Tanriover, Dilek Sengun, Ezel Berker

Erschienen in: Inflammation | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Statins possess a wide variety of pleiotropic properties that are independent of their lipid-lowering abilities such as attenuating inflammation, oxidative stress, coagulation, platelet aggregation and stimulating bone formation. The aim of the study is to evaluate the effect of statins on clinical periodontal parameters and gingival crevicular fluid (GCF) levels of IL-1β, IL-10, and myeloperoxidase (MPO) in inflammatory periodontal diseases. Seventy-nine subjects with hyperlipidemia and 48 systemically healthy controls (C) were included. Hyperlipidemic patients were either given a diet (HD) or prescribed statin (HS). Patients were classified into three subgroups as those who were periodontally healthy (h), who had gingivitis (g), or who had chronic periodontitis (p). Blood samples were collected for the measurement of lipid profiles. Plaque index (PI), gingival index (GI), probing pocket depth (PD), clinical attachment level (CAL), and percentage of bleeding on probing (BOP) were recorded. Gingival crevicular fluid levels of IL-1β, IL-10, and MPO were measured in order to determine the anti-inflammatory and antioxidant effects of statins. Probing depth values of the HSp group were significantly lower than those of the Cp group. Percentage of BOP of the HSg group was significantly lower than those of the HDg and Cg groups. While the IL-1β level of the HSp group was significantly lower than that of the HDp group, IL-10 levels of the HSg group were significantly higher than those of the HDg group. MPO levels were significantly lower in the HSg group when compared to those in the HDg and Cg groups. Statin use decreased the IL-1β and MPO levels and enhanced IL-10 in GCF. It can be suggested that statins may attenuate periodontal inflammation and progression of periodontal inflammation.
Literatur
1.
Zurück zum Zitat Genco, R.J. 1992. Host responses in periodontal diseases: current concepts. Journal of Periodontology 63: 338–55.CrossRefPubMed Genco, R.J. 1992. Host responses in periodontal diseases: current concepts. Journal of Periodontology 63: 338–55.CrossRefPubMed
2.
Zurück zum Zitat Okada, H., and S. Murakami. 1998. Cytokine expression in periodontal health and disease. Critical Reviews in Oral Biology and Medicine 9: 248–66.CrossRefPubMed Okada, H., and S. Murakami. 1998. Cytokine expression in periodontal health and disease. Critical Reviews in Oral Biology and Medicine 9: 248–66.CrossRefPubMed
3.
Zurück zum Zitat Loos, B.G., J. Craandijk, F.J. Hoek, P.M. Wertheim-van Dillen, and U. van der Velden. 2000. Elevation of systemic markers related to cardiovascular diseases in the peripheral blood of periodontitis patients. Journal of Periodontology 71: 1528–34.CrossRefPubMed Loos, B.G., J. Craandijk, F.J. Hoek, P.M. Wertheim-van Dillen, and U. van der Velden. 2000. Elevation of systemic markers related to cardiovascular diseases in the peripheral blood of periodontitis patients. Journal of Periodontology 71: 1528–34.CrossRefPubMed
4.
Zurück zum Zitat Quist-Paulsen, P. 2010. Statins and inflammation: an update. Current Opinion in Cardiology 25: 399–405.CrossRefPubMed Quist-Paulsen, P. 2010. Statins and inflammation: an update. Current Opinion in Cardiology 25: 399–405.CrossRefPubMed
5.
6.
Zurück zum Zitat Mundy, G., R. Garrett, S. Harris, J. Chan, D. Chen, G. Rossini, et al. 1999. Stimulation of bone formation in vitro and in rodents by statins. Science 286: 1946–9.CrossRefPubMed Mundy, G., R. Garrett, S. Harris, J. Chan, D. Chen, G. Rossini, et al. 1999. Stimulation of bone formation in vitro and in rodents by statins. Science 286: 1946–9.CrossRefPubMed
7.
Zurück zum Zitat Lindy, O., K. Suomalainen, M. Makela, and S. Lindy. 2008. Statin use is associated with fewer periodontal lesions: a retrospective study. BMC Oral Health 8: 16.CrossRefPubMedPubMedCentral Lindy, O., K. Suomalainen, M. Makela, and S. Lindy. 2008. Statin use is associated with fewer periodontal lesions: a retrospective study. BMC Oral Health 8: 16.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Saxlin, T., L. Suominen-Taipale, M. Knuuttila, P. Alha, and P. Ylostalo. 2009. Dual effect of statin medication on the periodontium. Journal of Clinical Periodontology 36: 997–1003.CrossRefPubMed Saxlin, T., L. Suominen-Taipale, M. Knuuttila, P. Alha, and P. Ylostalo. 2009. Dual effect of statin medication on the periodontium. Journal of Clinical Periodontology 36: 997–1003.CrossRefPubMed
9.
Zurück zum Zitat Saver, B.G., P.P. Hujoel, J. Cunha-Cruz, and G. Maupome. 2007. Are statins associated with decreased tooth loss in chronic periodontitis? Journal of Clinical Periodontology 34: 214–9.CrossRefPubMed Saver, B.G., P.P. Hujoel, J. Cunha-Cruz, and G. Maupome. 2007. Are statins associated with decreased tooth loss in chronic periodontitis? Journal of Clinical Periodontology 34: 214–9.CrossRefPubMed
10.
Zurück zum Zitat Meisel, P., H.K. Kroemer, M. Nauck, B. Holtfreter, and T. Kocher. 2014. Tooth loss, periodontitis, and statins in a population-based follow-up study. Journal of Periodontology 85: e160–8.CrossRefPubMed Meisel, P., H.K. Kroemer, M. Nauck, B. Holtfreter, and T. Kocher. 2014. Tooth loss, periodontitis, and statins in a population-based follow-up study. Journal of Periodontology 85: e160–8.CrossRefPubMed
11.
Zurück zum Zitat Sangwan, A., S. Tewari, H. Singh, R.K. Sharma, and S.C. Narula. 2013. Periodontal status and hyperlipidemia: statin users versus non-users. Journal of Periodontology 84: 3–12.CrossRefPubMed Sangwan, A., S. Tewari, H. Singh, R.K. Sharma, and S.C. Narula. 2013. Periodontal status and hyperlipidemia: statin users versus non-users. Journal of Periodontology 84: 3–12.CrossRefPubMed
12.
Zurück zum Zitat Fentoglu, O., B.K. Koroglu, H. Hicyilmaz, T. Sert, M. Ozdem, R. Sutcu, et al. 2011. Pro-inflammatory cytokine levels in association between periodontal disease and hyperlipidaemia. Journal of Clinical Periodontology 38: 8–16.CrossRefPubMed Fentoglu, O., B.K. Koroglu, H. Hicyilmaz, T. Sert, M. Ozdem, R. Sutcu, et al. 2011. Pro-inflammatory cytokine levels in association between periodontal disease and hyperlipidaemia. Journal of Clinical Periodontology 38: 8–16.CrossRefPubMed
13.
Zurück zum Zitat Suresh, S., S. Narayana, P. Jayakumar, U. Sudhakar, and V. Pramod. 2013. Evaluation of anti-inflammatory effect of statins in chronic periodontitis. Indian Journal of Pharmacology 45: 391–4.CrossRefPubMedPubMedCentral Suresh, S., S. Narayana, P. Jayakumar, U. Sudhakar, and V. Pramod. 2013. Evaluation of anti-inflammatory effect of statins in chronic periodontitis. Indian Journal of Pharmacology 45: 391–4.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Ebersole, J.L., R.E. Singer, B. Steffensen, T. Filloon, and K.S. Kornman. 1993. Inflammatory mediators and immunoglobulins in GCF from healthy, gingivitis and periodontitis sites. Journal of Periodontal Research 28: 543–6.CrossRefPubMed Ebersole, J.L., R.E. Singer, B. Steffensen, T. Filloon, and K.S. Kornman. 1993. Inflammatory mediators and immunoglobulins in GCF from healthy, gingivitis and periodontitis sites. Journal of Periodontal Research 28: 543–6.CrossRefPubMed
15.
Zurück zum Zitat Stashenko, P., J.J. Jandinski, P. Fujiyoshi, J. Rynar, and S.S. Socransky. 1991. Tissue levels of bone resorptive cytokines in periodontal disease. Journal of Periodontology 62: 504–9.CrossRefPubMed Stashenko, P., J.J. Jandinski, P. Fujiyoshi, J. Rynar, and S.S. Socransky. 1991. Tissue levels of bone resorptive cytokines in periodontal disease. Journal of Periodontology 62: 504–9.CrossRefPubMed
16.
Zurück zum Zitat de Araujo Junior, R.F., T.O. Souza, L.M. de Moura, K.P. Torres, L.B. de Souza, S. Alves Mdo, et al. 2013. Atorvastatin decreases bone loss, inflammation and oxidative stress in experimental periodontitis. PloS One 8, e75322.CrossRefPubMed de Araujo Junior, R.F., T.O. Souza, L.M. de Moura, K.P. Torres, L.B. de Souza, S. Alves Mdo, et al. 2013. Atorvastatin decreases bone loss, inflammation and oxidative stress in experimental periodontitis. PloS One 8, e75322.CrossRefPubMed
17.
Zurück zum Zitat Moore, K.W., A. O’Garra, R. de Waal Malefyt, P. Vieira, and T.R. Mosmann. 1993. Interleukin-10. Annual Review of Immunology 11: 165–90.CrossRefPubMed Moore, K.W., A. O’Garra, R. de Waal Malefyt, P. Vieira, and T.R. Mosmann. 1993. Interleukin-10. Annual Review of Immunology 11: 165–90.CrossRefPubMed
18.
Zurück zum Zitat Cassatella, M.A., L. Meda, S. Bonora, M. Ceska, and G. Constantin. 1993. Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 beta in mediating the production of IL-8 triggered by lipopolysaccharide. Journal of Experimental Medicine 178: 2207–11.CrossRefPubMed Cassatella, M.A., L. Meda, S. Bonora, M. Ceska, and G. Constantin. 1993. Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 beta in mediating the production of IL-8 triggered by lipopolysaccharide. Journal of Experimental Medicine 178: 2207–11.CrossRefPubMed
19.
Zurück zum Zitat Lacraz, S., L.P. Nicod, R. Chicheportiche, H.G. Welgus, and J.M. Dayer. 1995. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. Journal of Clinical Investigation 96: 2304–10.CrossRefPubMedPubMedCentral Lacraz, S., L.P. Nicod, R. Chicheportiche, H.G. Welgus, and J.M. Dayer. 1995. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. Journal of Clinical Investigation 96: 2304–10.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Li, J.J., and C.H. Fang. 2005. Effects of 4 weeks of atorvastatin administration on the antiinflammatory cytokine interleukin-10 in patients with unstable angina. Clinical Chemistry 51: 1735–8.CrossRefPubMed Li, J.J., and C.H. Fang. 2005. Effects of 4 weeks of atorvastatin administration on the antiinflammatory cytokine interleukin-10 in patients with unstable angina. Clinical Chemistry 51: 1735–8.CrossRefPubMed
21.
Zurück zum Zitat Tekin, A., N. Sezgin, M.T. Katircibasi, G. Tekin, Y. Colkesen, A.T. Sezgin, et al. 2008. Short-term effects of fluvastatin therapy on plasma interleukin-10 levels in patients with chronic heart failure. Coronary Artery Disease 19: 513–9.CrossRefPubMed Tekin, A., N. Sezgin, M.T. Katircibasi, G. Tekin, Y. Colkesen, A.T. Sezgin, et al. 2008. Short-term effects of fluvastatin therapy on plasma interleukin-10 levels in patients with chronic heart failure. Coronary Artery Disease 19: 513–9.CrossRefPubMed
22.
Zurück zum Zitat Sorsa, T., L. Tjaderhane, Y.T. Konttinen, A. Lauhio, T. Salo, H.M. Lee, et al. 2006. Matrix metalloproteinases: contribution to pathogenesis, diagnosis and treatment of periodontal inflammation. Annali Medici 38: 306–21.CrossRef Sorsa, T., L. Tjaderhane, Y.T. Konttinen, A. Lauhio, T. Salo, H.M. Lee, et al. 2006. Matrix metalloproteinases: contribution to pathogenesis, diagnosis and treatment of periodontal inflammation. Annali Medici 38: 306–21.CrossRef
23.
Zurück zum Zitat Steinberg, D., S. Parthasarathy, T.E. Carew, J.C. Khoo, and J.L. Witztum. 1989. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. New England Journal of Medicine 320: 915–24.CrossRefPubMed Steinberg, D., S. Parthasarathy, T.E. Carew, J.C. Khoo, and J.L. Witztum. 1989. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. New England Journal of Medicine 320: 915–24.CrossRefPubMed
24.
Zurück zum Zitat Davignon, J., R.F. Jacob, and R.P. Mason. 2004. The antioxidant effects of statins. Coronary Artery Disease 15: 251–8.CrossRefPubMed Davignon, J., R.F. Jacob, and R.P. Mason. 2004. The antioxidant effects of statins. Coronary Artery Disease 15: 251–8.CrossRefPubMed
25.
Zurück zum Zitat Loe, H., and J. Silness. 1963. Periodontal disease in pregnancy. I. Prevalence and severity. Acta Odontologica Scandinavica 21: 533–51.CrossRefPubMed Loe, H., and J. Silness. 1963. Periodontal disease in pregnancy. I. Prevalence and severity. Acta Odontologica Scandinavica 21: 533–51.CrossRefPubMed
26.
Zurück zum Zitat Silness, J., and H. Loe. 1964. Periodontal disease in pregnancy. II. Correlation between oral hygiene and periodontal condition. Acta Odontologica Scandinavica 22: 121–35.CrossRefPubMed Silness, J., and H. Loe. 1964. Periodontal disease in pregnancy. II. Correlation between oral hygiene and periodontal condition. Acta Odontologica Scandinavica 22: 121–35.CrossRefPubMed
27.
Zurück zum Zitat Ainamo, J., and I. Bay. 1975. Problems and proposals for recording gingivitis and plaque. International Dental Journal 25: 229–35.PubMed Ainamo, J., and I. Bay. 1975. Problems and proposals for recording gingivitis and plaque. International Dental Journal 25: 229–35.PubMed
28.
Zurück zum Zitat Suzuki, K., H. Ota, S. Sasagawa, T. Sakatani, and T. Fujikura. 1983. Assay method for myeloperoxidase in human polymorphonuclear leukocytes. Analytical Biochemistry 132: 345–52.CrossRefPubMed Suzuki, K., H. Ota, S. Sasagawa, T. Sakatani, and T. Fujikura. 1983. Assay method for myeloperoxidase in human polymorphonuclear leukocytes. Analytical Biochemistry 132: 345–52.CrossRefPubMed
29.
Zurück zum Zitat Laufs, U., V. La Fata, J. Plutzky, and J.K. Liao. 1998. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97: 1129–35.CrossRefPubMed Laufs, U., V. La Fata, J. Plutzky, and J.K. Liao. 1998. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97: 1129–35.CrossRefPubMed
30.
Zurück zum Zitat Cunha-Cruz, J., B. Saver, G. Maupome, and P.P. Hujoel. 2006. Statin use and tooth loss in chronic periodontitis patients. Journal of Periodontology 77: 1061–6.CrossRefPubMed Cunha-Cruz, J., B. Saver, G. Maupome, and P.P. Hujoel. 2006. Statin use and tooth loss in chronic periodontitis patients. Journal of Periodontology 77: 1061–6.CrossRefPubMed
31.
Zurück zum Zitat de Lima Oliveira, A.P., M. de Faveri, L.C. Gursky, M.J. Mestnik, M. Feres, A.D. Haffajee, et al. 2012. Effects of periodontal therapy on GCF cytokines in generalized aggressive periodontitis subjects. Journal of Clinical Periodontology 39: 295–302.CrossRefPubMed de Lima Oliveira, A.P., M. de Faveri, L.C. Gursky, M.J. Mestnik, M. Feres, A.D. Haffajee, et al. 2012. Effects of periodontal therapy on GCF cytokines in generalized aggressive periodontitis subjects. Journal of Clinical Periodontology 39: 295–302.CrossRefPubMed
32.
Zurück zum Zitat Cao, C.F., and Q.T. Smith. 1989. Crevicular fluid myeloperoxidase at healthy, gingivitis and periodontitis sites. Journal of Clinical Periodontology 16: 17–20.CrossRefPubMed Cao, C.F., and Q.T. Smith. 1989. Crevicular fluid myeloperoxidase at healthy, gingivitis and periodontitis sites. Journal of Clinical Periodontology 16: 17–20.CrossRefPubMed
33.
Zurück zum Zitat Nizam, N., P. Gumus, J. Pitkanen, T. Tervahartiala, T. Sorsa, and N. Buduneli. 2014. Serum and salivary matrix metalloproteinases, neutrophil elastase, myeloperoxidase in patients with chronic or aggressive periodontitis. Inflammation 37: 1771–8.CrossRefPubMed Nizam, N., P. Gumus, J. Pitkanen, T. Tervahartiala, T. Sorsa, and N. Buduneli. 2014. Serum and salivary matrix metalloproteinases, neutrophil elastase, myeloperoxidase in patients with chronic or aggressive periodontitis. Inflammation 37: 1771–8.CrossRefPubMed
34.
Zurück zum Zitat Dalcico, R., A.M. de Menezes, O.B. Deocleciano, R.B. Oria, M.L. Vale, R.A. Ribeiro, et al. 2013. Protective mechanisms of simvastatin in experimental periodontal disease. Journal of Periodontology 84: 1145–57.CrossRefPubMed Dalcico, R., A.M. de Menezes, O.B. Deocleciano, R.B. Oria, M.L. Vale, R.A. Ribeiro, et al. 2013. Protective mechanisms of simvastatin in experimental periodontal disease. Journal of Periodontology 84: 1145–57.CrossRefPubMed
Metadaten
Titel
Statins and IL-1β, IL-10, and MPO Levels in Gingival Crevicular Fluid: Preliminary Results
verfasst von
Vuslat Cicek Ari
Yagmur Deniz Ilarslan
Baran Erman
Bahram Sarkarati
Ilhan Tezcan
Erdem Karabulut
Serife Gul Oz
Mine Durusu Tanriover
Dilek Sengun
Ezel Berker
Publikationsdatum
11.06.2016
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 4/2016
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-016-0390-7

Weitere Artikel der Ausgabe 4/2016

Inflammation 4/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.